Compare PMT & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | AGMB |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 652.5M |
| IPO Year | 2009 | 2024 |
| Metric | PMT | AGMB |
|---|---|---|
| Price | $9.68 | $15.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $13.50 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.1M | 143.2K |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $351,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.55 | $17.86 |
| P/E Ratio | $24.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.05 | $8.75 |
| 52 Week High | $13.80 | $17.82 |
| Indicator | PMT | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 65.59 |
| Support Level | $9.11 | $9.54 |
| Resistance Level | $9.83 | $17.31 |
| Average True Range (ATR) | 0.17 | 0.97 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 86.24 | 97.53 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.